<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02750748</url>
  </required_header>
  <id_info>
    <org_study_id>Naltexone-Ph1a-002</org_study_id>
    <nct_id>NCT02750748</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Evaluation of Intranasal, Intramuscular, and Oral Naltrexone in Healthy Volunteers</brief_title>
  <official_title>Pharmacokinetic Evaluation of Intranasal, Intramuscular, and Oral Naltrexone in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute on Drug Abuse (NIDA)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the pharmacokinetics of 2 intranasal doses and 1 oral dose of naltrexone
      compared to an intramuscular dose of naltrexone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Concentration (Cmax)</measure>
    <time_frame>48 hours</time_frame>
    <description>Measurement of serum naltrexone prior to dosing and at times 2, 3, 4, 6, 8, 12, 16, 24, 30, 36 and 48 hours after naltrexone administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Concentration (Tmax)</measure>
    <time_frame>48 hours</time_frame>
    <description>Measurement of serum naltrexone prior to dosing and at times 2, 3, 4, 6, 8, 12, 16, 24, 30, 36 and 48 hours after naltrexone administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Concentration (AUC 0-t)</measure>
    <time_frame>48 hours</time_frame>
    <description>Measurement of serum naltrexone prior to dosing and at times 2, 3, 4, 6, 8, 12, 16, 24, 30, 36 and 48 hours after naltrexone administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Concentration (AUC 0-inf)</measure>
    <time_frame>48 hours</time_frame>
    <description>Measurement of serum naltrexone prior to dosing and at times 2, 3, 4, 6, 8, 12, 16, 24, 30, 36 and 48 hours after naltrexone administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Maximum of 18 days</time_frame>
    <description>Will be reported from the start of the first session to follow-up visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>12 days</time_frame>
    <description>Measured before and after naltrexone administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-lead electrocardiogram</measure>
    <time_frame>12 days</time_frame>
    <description>Measured before and after naltrexone administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal Irritation Scoring</measure>
    <time_frame>5 days</time_frame>
    <description>Will be reported from the start of the first session to follow-up visit</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Opioid-Related Disorders</condition>
  <arm_group>
    <arm_group_label>4mg Intranasal Naltrexone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administer one 0.1 mL spray of a 40 mg/mL solution in one nostril</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4mg Intranasal Naltrexone with Intravail</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administer 0.1 mL spray of a 40 mg/mL solution with 0.25% Intravail in one nostril</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2mg Intramuscular Naltrexone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administer 2 mg formulation intramuscularly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50mg Naltrexone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administer 50mg formulation orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone</intervention_name>
    <arm_group_label>4mg Intranasal Naltrexone</arm_group_label>
    <arm_group_label>4mg Intranasal Naltrexone with Intravail</arm_group_label>
    <arm_group_label>2mg Intramuscular Naltrexone</arm_group_label>
    <arm_group_label>50mg Naltrexone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intravail</intervention_name>
    <arm_group_label>4mg Intranasal Naltrexone with Intravail</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females 18 to 55 years of age, inclusive.

          -  Provide written informed consent.

          -  BMI ranging from 18 to 30 kg/m2, inclusive.

          -  Adequate venous access.

          -  No clinically significant concurrent medical conditions determined by medical history,
             physical examination, clinical laboratory examination, vital signs, and 12-lead ECG.

          -  Male subjects must agree to use an acceptable method of contraception with female
             partners as well as not to donate sperm throughout the study and for 90 days after the
             last study drug administration. Female subject of childbearing potential must agree to
             use an acceptable method of birth control throughout the study and for 30 days after
             the last study drug administration. Oral contraceptives are prohibited.

          -  Agree not to ingest alcohol, drinks containing xanthine &gt;500 mg/day (e.g., Coca ColaÂ®,
             coffee, tea, etc.), or grapefruit/grapefruit juice.

          -  Participate in strenuous exercise 72 hours prior to admission through the last blood
             draw of the study.

        Exclusion Criteria:

          -  Please contact site for more information
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nora Chiang, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>National Institute on Drug Abuse (NIDA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vince and Associates Clinical Research, Inc.</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2016</study_first_submitted>
  <study_first_submitted_qc>April 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2016</study_first_posted>
  <last_update_submitted>January 11, 2017</last_update_submitted>
  <last_update_submitted_qc>January 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

